SG11202112952SA - Heterobicyclic inhibitors of mat2a and methods of use for treating cancer - Google Patents
Heterobicyclic inhibitors of mat2a and methods of use for treating cancerInfo
- Publication number
- SG11202112952SA SG11202112952SA SG11202112952SA SG11202112952SA SG11202112952SA SG 11202112952S A SG11202112952S A SG 11202112952SA SG 11202112952S A SG11202112952S A SG 11202112952SA SG 11202112952S A SG11202112952S A SG 11202112952SA SG 11202112952S A SG11202112952S A SG 11202112952SA
- Authority
- SG
- Singapore
- Prior art keywords
- mat2a
- methods
- treating cancer
- heterobicyclic
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855395P | 2019-05-31 | 2019-05-31 | |
| PCT/US2020/035036 WO2020243376A1 (en) | 2019-05-31 | 2020-05-29 | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112952SA true SG11202112952SA (en) | 2021-12-30 |
Family
ID=72179154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112952SA SG11202112952SA (en) | 2019-05-31 | 2020-05-29 | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220251081A1 (he) |
| EP (1) | EP3976611A1 (he) |
| JP (1) | JP2022534989A (he) |
| AR (1) | AR119046A1 (he) |
| AU (1) | AU2020284018A1 (he) |
| BR (1) | BR112021023825A2 (he) |
| CA (1) | CA3142340A1 (he) |
| CO (1) | CO2021017981A2 (he) |
| CR (1) | CR20210670A (he) |
| IL (1) | IL288395A (he) |
| JO (1) | JOP20210317A1 (he) |
| MA (1) | MA56050A (he) |
| PE (1) | PE20220387A1 (he) |
| SG (1) | SG11202112952SA (he) |
| TW (1) | TW202110841A (he) |
| WO (1) | WO2020243376A1 (he) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061834T2 (hu) * | 2018-12-27 | 2023-08-28 | Servier Lab | MAT2A aza-heterobiciklusos inhibitorai és alkalmazási eljárások rák kezelésére |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115960099A (zh) * | 2020-09-24 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| WO2022109001A1 (en) | 2020-11-18 | 2022-05-27 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| TW202227443A (zh) * | 2020-12-31 | 2022-07-16 | 中國商江蘇先聲藥業有限公司 | 三環類化合物及用途 |
| WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| CN117295734A (zh) * | 2021-04-30 | 2023-12-26 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| TW202327600A (zh) | 2021-10-20 | 2023-07-16 | 香港商英科智能有限公司 | 甲硫胺酸腺苷轉移酶２ａ（ｍａｔ２ａ）抑制劑及其用途 |
| WO2023083210A1 (zh) * | 2021-11-09 | 2023-05-19 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| WO2023116696A1 (zh) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| TW202333696A (zh) * | 2022-01-26 | 2023-09-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 用於治療ｍｔａｐ缺失型癌症的甲硫氨酸腺苷轉移酶２ａ抑制劑 |
| WO2023169554A1 (zh) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| KR20240051860A (ko) * | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| CN116239541B (zh) * | 2023-05-11 | 2023-07-21 | 英矽智能科技(上海)有限公司 | N-苯基-2-氧代喹唑啉类化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| MXPA03001821A (es) * | 2000-08-31 | 2003-06-04 | Hoffmann La Roche | 7-oxo-piridopirimidinas como inhibidores de prolieferacion celular. |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2008078249A1 (en) * | 2006-12-21 | 2008-07-03 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
| WO2008156726A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Inhibitors of janus kinases |
| UA127059C2 (uk) * | 2018-03-30 | 2023-03-29 | Ле Лаборатуар Сервьє | Гетеробіциклічні інгібітори mat2a і способи використання для лікування злоякісної пухлини |
-
2020
- 2020-05-29 AU AU2020284018A patent/AU2020284018A1/en not_active Abandoned
- 2020-05-29 JO JOP/2021/0317A patent/JOP20210317A1/ar unknown
- 2020-05-29 SG SG11202112952SA patent/SG11202112952SA/en unknown
- 2020-05-29 AR ARP200101527A patent/AR119046A1/es unknown
- 2020-05-29 MA MA056050A patent/MA56050A/fr unknown
- 2020-05-29 TW TW109117971A patent/TW202110841A/zh unknown
- 2020-05-29 US US17/615,255 patent/US20220251081A1/en active Pending
- 2020-05-29 EP EP20760599.9A patent/EP3976611A1/en not_active Withdrawn
- 2020-05-29 PE PE2021001990A patent/PE20220387A1/es unknown
- 2020-05-29 CA CA3142340A patent/CA3142340A1/en not_active Abandoned
- 2020-05-29 CR CR20210670A patent/CR20210670A/es unknown
- 2020-05-29 BR BR112021023825A patent/BR112021023825A2/pt not_active Application Discontinuation
- 2020-05-29 WO PCT/US2020/035036 patent/WO2020243376A1/en active Search and Examination
- 2020-05-29 JP JP2021570897A patent/JP2022534989A/ja active Pending
-
2021
- 2021-11-25 IL IL288395A patent/IL288395A/he unknown
- 2021-12-28 CO CONC2021/0017981A patent/CO2021017981A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288395A (he) | 2022-01-01 |
| CA3142340A1 (en) | 2020-12-03 |
| JP2022534989A (ja) | 2022-08-04 |
| WO2020243376A1 (en) | 2020-12-03 |
| AR119046A1 (es) | 2021-11-17 |
| PE20220387A1 (es) | 2022-03-18 |
| AU2020284018A1 (en) | 2022-01-27 |
| MA56050A (fr) | 2022-04-06 |
| BR112021023825A2 (pt) | 2022-02-08 |
| US20220251081A1 (en) | 2022-08-11 |
| CO2021017981A2 (es) | 2022-04-19 |
| JOP20210317A1 (ar) | 2023-01-30 |
| EP3976611A1 (en) | 2022-04-06 |
| CR20210670A (es) | 2022-02-11 |
| TW202110841A (zh) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277665A (he) | מעכבים הטרוציקלים של mat2a ושיטות לשימוש עבור טיפול בסרטן | |
| IL288395A (he) | מעכבים הטרוביציקליים של mat2a ושיטות לשימוש לטיפול בסרטן | |
| IL284324A (he) | מעכבי mat2a אזא-הטרוביציקליים ושיטות לשימוש לטיפול בסרטן | |
| IL284326A (he) | מעכבי mat2a אזא-הטרוביציקליים ושיטות לשימוש לטיפול בסרטן | |
| IL272948A (he) | מעכבי enpp1 והשימוש בהם לטיפול בסרטן | |
| IL254736B (he) | תרכובות של נגזרת של אימידאזול [1,2–c]פירימידין, מעכבי 1lsd, תרכובת רוקחות הכוללת אותם ושימוש לטיפול בסרטן | |
| IL288061A (he) | תרכובות ושיטות לטיפול ב covid-19 | |
| EP3464643A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3890749A4 (en) | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT | |
| IL288707A (he) | שיטות לשימוש במעכבי rad51 לטיפול בסרטן הלבלב | |
| HK1244436A1 (zh) | 治療癌症的hsp90抑制劑和pd-1抑制劑的組合療法 | |
| IL308195A (he) | מעכבי ras לטיפול בסרטן | |
| IL274198A (he) | שימוש במעכבי הנוקס לטיפול בסרטן | |
| IL277918A (he) | שילוב של מעכבי lif ומעכבי pd-1 axis לשימוש בטיפול בסרטן | |
| EP3630080A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL291424A (he) | שימוש במעכבי dkk-1 לטיפול בסרטן | |
| IL289251A (he) | שיטות ותכשירים לטיפול בסרטן הלבלב | |
| IL288665A (he) | שיטות לטיפול בסרטן באמצעות מעכבי prmt5 | |
| IL288003A (he) | שיטות לטיפול בסרטן בשימוש במעכבי chk1 | |
| IL287538A (he) | תכשירים ושיטות לטיפול בסרטן | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| EP4114864A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| GB201506248D0 (en) | Medical uses and methods for treating cancer using monopolar spindle 1 (MPS1) Kase Inhibitors | |
| EP4097137A4 (en) | COMBINATIONS OF EGFR INHIBITORS AND ROR1 INHIBITORS FOR THE TREATMENT OF CANCER |